Feedback / Questions
migaldendranib subcutaneous (D-4517.2 SC) - Ashvattha Therap
https://www.globenewswire.com/news-release/2025/02/10/3023403/0/en/Ashvattha-Presents-Positive-Phase-2-Data-for-Subcutaneous-Migaldendranib-at-Angiogenesis-2025-Conference.html
Feb 10, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next